We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alnylam Pharmaceuticals Inc | NASDAQ:ALNY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.15 | -1.41% | 150.185 | 150.01 | 150.28 | 152.82 | 149.58 | 152.82 | 103,998 | 18:35:13 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
MARAGANORE JOHN |
2. Issuer Name
and
Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer |
C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
CAMBRIDGE, MA 02142 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 5/23/2014 | G | V | 1700 | D | $0 | 104620 | D | ||
Common Stock | 9/17/2014 | M (1) | 56834 | A | $7.47 | 161454 | D | |||
Common Stock | 9/17/2014 | S (1) | 3400 | D | $74.736 (2) | 158054 | D | |||
Common Stock | 9/17/2014 | S (1) | 13899 | D | $75.6452 (3) | 144155 | D | |||
Common Stock | 9/17/2014 | S (1) | 23286 | D | $76.5403 (4) | 120869 | D | |||
Common Stock | 9/17/2014 | S (1) | 15849 | D | $77.7144 (5) | 105020 | D | |||
Common Stock | 9/17/2014 | S (1) | 400 | D | $78.1044 (6) | 104620 | D | |||
Common Stock | 9/18/2014 | M (1) | 56834 | A | $7.47 | 161454 | D | |||
Common Stock | 9/18/2014 | S (1) | 18962 | D | $78.118 (7) | 142492 | D | |||
Common Stock | 9/18/2014 | S (1) | 37872 | D | $79.2287 (8) | 104620 | D | |||
Common Stock | 2689 | I | By Managed Account (9) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (Right to Buy) | $7.47 | 9/17/2014 | M (1) | 56834 | 12/21/2005 | 12/21/2014 (1) | Common Stock | 56834 | $0 | 56834 | D | ||||
Stock Option (Right to Buy) | $7.47 | 9/18/2014 | M (1) | 56834 | 12/21/2005 | 12/21/2014 (1) | Common Stock | 56834 | $0 | 0 | D |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
MARAGANORE JOHN
C/O ALNYLAM PHARMACEUTICALS, INC. 300 THIRD STREET CAMBRIDGE, MA 02142 |
X |
|
Chief Executive Officer |
|
Signatures
|
||
/s/ Michael P. Mason, Attorney-in-Fact for John M. Maraganore | 9/19/2014 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Alnylam Pharmaceuticals Chart |
1 Month Alnylam Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions